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(10), might confer a high degree of 
virulence to these strains. It also might 
explain the severity of the clinical 
ﬁ   ndings associated with STEC 
O104:H4 infections.
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Complicated 
Pandemic (H1N1) 
2009 during 
Pregnancy, Taiwan
To the Editor: Pregnant women 
with pandemic (H1N1) 2009 virus 
infection are at increased risk for 
severe illness and complications (1–
3). Recent reports have shown that 
this infection causes disproportionate 
illness and death in pregnant women 
and has been associated with adverse 
fetal and neonatal outcomes. We 
characterized the severity of pandemic 
(H1N1) 2009 virus infection among 
pregnant women in Taiwan.
Complicated inﬂ  uenza infection, 
deﬁ   ned as inﬂ   uenza-like illness and 
evidence of pneumonia, neurologic 
symptoms, myopericarditis, or 
invasive bacterial infections, has 
been a notiﬁ   able disease in Taiwan 
since 2002 (4). We reviewed reports 
and medical records of complicated 
pandemic (H1N1) 2009 virus 
infection, conﬁ   rmed by real-time 
reverse transcription PCR in women 
15–49 years of age who had onset 
of illness during July 1–December 
31, 2009. Data were obtained for 
demographics; pregnancy status and 
outcome; gestational age at illness 
onset; preexisting medical conditions; 
onset of illness; treatment; and 
severity, including intensive care unit 
(ICU) admission.
To calculate rates of complicated 
pandemic (H1N1) 2009 virus 
infection, we estimated the pregnant 
population during July 1–December 
31, 2009, by using the National Health 
Insurance computerized database 
for Taiwan (5). Women who were 
15–49 years of age and had been 
assigned International Classiﬁ  cation 
of Diseases, 9th Revision, Clinical 
Modiﬁ  cation (www.cdc.gov/nchs/icd/
icd9cm.htm), codes of V22* (normal 
pregnancy) and V23* (supervision of 
high-risk pregnancy) during the study 
were considered pregnant. Number of 
nonpregnant women was estimated by 
subtracting the calculated number of 
pregnant women from the number of 
women 15–49 years of age from 2009 
household registration data (6). We 
estimated 95% conﬁ  dence  intervals 
(CIs) for rates by using exact binomial 
methods.
During July 1–December 31, 
2009, data were reported for 10 
pregnant women and 138 nonpregnant 
women 15–49 years of age who had 
conﬁ   rmed, complicated pandemic 
(H1N1) 2009 virus infections. Dates 
of illness onset ranged from August 3 
through December 31, 2009. Median 
age of the 10 pregnant women was 24.5 
years (range 22–32 years), and median 
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gestational age at illness onset was 
24 weeks (range 5–37 weeks). Other 
than pregnancy, none of these women 
had high-risk conditions for inﬂ  uenza 
complications recognized by the 
Advisory Committee on Immunization 
Practices (7). Seven women gave birth 
during hospitalization; 4 fetuses were 
stillborn, and 3 were live-born. At 
birth, the 3 live-born infants were at 
27, 32, and 37 weeks’ gestation and 
weighed 824, 1,850, and 3,270 g, 
respectively; all were admitted to a 
neonatal ICU.
Four (40%) pregnant and 84 
(63%) nonpregnant women received 
oseltamivir treatment within 48 hours 
of illness onset (p = 0.19) (Table). 
Acute respiratory distress syndrome 
developed, mechanical ventilation 
was required, and extracorporeal 
membrane oxygenation was required 
in a higher proportion of pregnant 
women than nonpregnant women. 
Median length of hospital stay was 8 
days (range 3–47 days) for pregnant 
women and 5 days (range 0–100 days) 
for nonpregnant women (p = 0.03). 
Five (50%) pregnant and 31 (22%) 
nonpregnant women were admitted to 
an ICU (p = 0.06); 3 (30%) pregnant 
women and 5 (4%) nonpregnant 
women died (p = 0.01).
There were 168,364 pregnant 
women and 6,220,197 nonpregnant 
women 15–49 years of age in Taiwan 
throughout the study period. The rate 
of complicated pandemic (H1N1) 
2009 virus infection was 5.94 per 
100,000 pregnant women (95% CI 
2.85–10.92) and 2.22 per 100,000 
nonpregnant women (95% CI, 1.86–
2.62). Pregnant women were at greater 
risk for complicated pandemic (H1N1) 
2009 virus infection than nonpregnant 
women (risk ratio 2.68, 95% CI 1.41–
5.09).
Findings from this study have 
several limitations. Ascertainment of 
patients with complicated pandemic 
(H1N1) 2009 virus infection relied 
on passive surveillance. Therefore, 
data collection varied in completeness 
and quality between hospitals and 
different surveillance periods. The 
small number of pregnant women 
with conﬁ  rmed complicated pandemic 
(H1N1) 2009 virus infection limited 
statistical power for stratiﬁ  ed analyses 
by patient demographics and other 
characteristics. On November 1, 
2009, Taiwan concurrently began 
a nationwide vaccination program 
against pandemic (H1N1) 2009 (8). As 
of December 31, 2009, a total of 8% of 
pregnant women and 13% of persons 
>15 years of age had been vaccinated 
(Taiwan Centers for Disease Control, 
unpub. data). Calculated rates of 
complicated pandemic (H1N1) 2009 
virus infection could be affected by 
variable vaccine coverage among 
pregnant and nonpregnant women.
In Taiwan, oseltamivir treatment 
was provided free during the 2009 
inﬂ   uenza pandemic to patients with 
inﬂ  uenza-like illness who had positive 
results for inﬂ  uenza by rapid inﬂ  uenza 
diagnostic tests, signs that signal 
progression to severe diseases (9), 
and clinical evidence of complicated 
inﬂ  uenza infections. The government 
recommended that pregnant women 
receive the vaccine against pandemic 
(H1N1) 2009, regardless of stage of 
pregnancy, and made this group a 
priority. Our ﬁ   ndings are consistent 
with those of other studies (1–3) and 
suggest that pregnancy is a risk factor 
for severe or fatal pandemic (H1N1) 
2009 virus infection in Taiwan. These 
ﬁ   ndings justify policies to treat and 
vaccinate pregnant women against 
pandemic (H1N1) 2009.
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Table. Characteristics of women ages 15–49 y who had confirmed pandemic (H1N1) 
2009 infection, by pregnancy status, Taiwan, July 1–December 31, 2009* 
Characteristic
Pregnant,
n = 10 
Nonpregnant, 
n = 138  p value†
Age, y  24.5 (22–32) 27.5 (15–49)  0.39
ACIP high-risk condition other than 
pregnancy 
0 28 (20)  0.21
Pneumonia  9 (90)  134 (97)  0.30
  ARDS  5 (50)  14 (10)  0.003 
Admission to hospital  9 (90)  138 (100)  0.07
  Time from symptom onset to  
 hospitalization,  d 
2 (0–7)  2 (1–12)  0.78
  Length of hospital stay, d  8 (3–47)  5 (0–100)  0.03
Admission to ICU  5 (50)  31 (22)  0.06
  Length of ICU stay, d  16 (6–33)  5 (0–83)  0.07
Oseltamivir treatment  9 (90)  135 (98)  0.25
 <48 h after illness onset  4 (40)  84‡ (63) 0.19
Mechanical ventilation  5 (50)  19 (14)  0.01
ECMO 3 (30)  1 (1)  <0.001 
Death  3 (30)  5 (4)  0.01
  Time from illness onset to death, d  16 (2–37)  9 (1–32)  0.57
*Values are median (range) or no. (%). ACIP, Advisory Committee on Immunization Practices; 
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; ECMO, extracorporeal 
membrane oxygenation. 
†Medians were compared by using Wilcoxon rank-sum test, and proportions were compared by 
using Fisher exact test. 
‡For 4 nonpregnant women, information on date of initiation of oseltamivir treatment was unknown. LETTERS
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Pandemic (H1N1) 
2009 and Seasonal 
Inﬂ  uenza A (H3N2) 
in Children’s 
Hospital, Australia
To the Editor: We read with 
interest the report by Carcione et al. of 
clinical features of pandemic inﬂ  uenza 
A (H1N1) 2009 and comparison of 
these with 2009 seasonal inﬂ  uenza 
infection in a population-based 
study from Western Australia (1). 
Here we share our experience of 
hospitalizations for inﬂ   uenza in a 
tertiary care children’s hospital in 
Sydney, New South Wales, Australia, 
during the 3 peak inﬂ  uenza seasons of 
the last decade.
During the 2009 Southern 
Hemisphere single inﬂ  uenza  wave 
(June–September), we prospectively 
studied every child <15 years of age 
who was hospitalized with laboratory-
conﬁ  rmed inﬂ  uenza (74% had proven 
pandemic [H1N1] 2009) in Children’s 
Hospital at Westmead (CHW), Sydney, 
as part of a collaboration between the 
National Centre for Immunisation 
Research and Surveillance and the 
Australian Paediatric Surveillance 
Unit. The study was approved by the 
Human Research Ethics Committee at 
CHW and supported by the state (New 
South Wales) health department. Data 
from hospitalizations for seasonal 
inﬂ  uenza at CHW in 2003 and 2007 
(previous peaks in the last decade) 
were analyzed by using our previous 
studies and medical records (2–4). To 
compare pneumonia rates, we used 
the same case deﬁ  nitions in 2007 and 
2009 (radiologic changes consistent 
with pneumonia). Proportions were 
compared by using the χ2 statistic.
In 2009, the numbers of children 
with laboratory-conﬁ  rmed  inﬂ  uenza 
admitted to the hospital and to the 
pediatric intensive care unit (PICU) at 
CHW (226 and 22, respectively) were 
nearly double those admitted in 2007 
(122 and 12) but similar to the number 
in 2003 (257 and 22). The proportion 
of case-patients admitted to the PICU, 
the length of hospital stay, and the 
length of PICU stay were similar in 
2003, 2007, and 2009. 
In 2009, among the 226 inﬂ  uenza-
associated hospitalizations, 167 
(74%) were for pandemic (H1N1) 
2009 infection; in 2007, 119 of 122 
inﬂ  uenza-associated  hospitalizations 
were for seasonal inﬂ  uenza A (H3N2) 
infection (Table). During the 2009 
pandemic wave, of all children 
admitted with laboratory-conﬁ  rmed 
inﬂ  uenza, the proportion hospitalized 
with pandemic (H1N1) 2009 who 
were <6 months of age was similar to 
the proportion of children <6 months 
of age hospitalized with seasonal 
(H3N2) inﬂ  uenza in 2007 (21 [13%] of 
167 and 21 [18%] of 119, respectively; 
p = 0.31). The proportions of those >5 
years of age were signiﬁ  cantly higher 
(61 [37%] and 15 [13%]; p = 0.0001). 
However, the proportion of those 
>5 years of age admitted to PICU in 
2009 was less than in 2007 (10 [16%] 
of 61 vs. 3 [20%] of 15; p = 0.71). 
Similar percentages of children with 
preexisting conditions were admitted 
in 2009 and 2007 (47% and 49%, 
respectively). However, pneumonia 
was a more frequent complication in 
2009 than in 2007 (42 [25%] of 167 
vs. 15 [13%] of 119; p = 0.01). In 
2009, the proportion of children with 
pandemic (H1N1) 2009 who needed 
mechanical ventilation (7 [4%] of 167) 
was similar to the proportion in 2007 
who had seasonal inﬂ  uenza (H3N2) (6 
[5%] of 119; p = 0.77). Furthermore, 
no child at CHW in 2007 or in 2009 
received extracorporeal membrane 
oxygenation.
Vomiting occurred much more 
frequently in 2009 than in 2007 (59 
[35%] of 167 vs. 16  [13%] of 119; p 
= 0.0001). In 2009, of 62 children who 
did not exhibit vomiting when ﬁ  rst 
examined, and who were subsequently 
treated with antiviral drugs, only 1 had 
vomiting develop in the hospital. This 
condition resolved within hours, and 
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